✦ LIBER ✦

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

✍ Scribed by Jong-Mu Sun; Young-Woong Won; Seung Tae Kim; Jung Hoon Kim; Yoon-La Choi; Jeeyun Lee; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn

Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 304 KB
Volume: 137
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-010-0928-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of epidermal growth factor re

Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer

✍ Guo Jian; Zhou Songwen; Zhang Ling; Deng Qinfang; Zhang Jie; Tang Liang; Zhou Ca 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 354 KB

Detection of epidermal growth factor rec

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer

✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_